MYGN Q3'26 Earnings: revenue estimate is 191.33M USD

What happened

Myriad Genetics will report Q3'26 results on November 04 after the market closes, at 4:05 PM ET. The revenue estimate is 191.33 million USD, and the earnings per share estimate is (0.20) USD, which means an expected loss per share.

Confirmed

Global impact / market context

The revenue estimate is below prior reported levels, pointing to shrinking sales, and the negative earnings per share estimate means costs are expected to exceed profit. Investors will focus on whether spending is being controlled and whether sales stabilize.

Analyst inference

Prior quarters show revenue and earnings per share estimates often missed, with the latest quarter falling short on both. That pattern suggests expectations have already been lowered, so the reported figures and any forward guidance will shape investor positioning.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 191.33 million USD estimate when Myriad Genetics announces results on November 04 after the market closes. Confirmed
2. Watch for company guidance on future revenue and costs, since a forecast is a proposal about future performance rather than a confirmed result. Proposed
3. Watch whether the revenue decline slows compared with the prior quarter, which would suggest the business is stabilizing rather than shrinking further. Analyst inference

Evidence

• Original source link unavailable